Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704158 · ClinicalTrials.gov registry record · Phase 1
Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
A Phase 1 study, sponsored by CuraGen Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00704158 is a Phase 1 study that has completed, run by CuraGen Corporation. The registered enrollment target is 42 participants.
The verdict
NCT00704158, a Phase 1 study, has completed, sponsored by CuraGen Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial to further evaluate the safety and efficacy of CR011-vcMMAE.
Interventions
- DRUG CR011-vcMMAE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704158
The ClinicalTrials.gov registry entry for NCT00704158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CuraGen Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CR011-vcMMAE is the first listed.
NCT00704158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704158 about?
NCT00704158 is a clinical study titled "Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer". This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer p...
What is the current status of trial NCT00704158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00704158?
The interventions under investigation include: CR011-vcMMAE (DRUG).
Who is sponsoring clinical trial NCT00704158?
This trial is sponsored by CuraGen Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.